• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

MammoReader clears FDA

Article

Intelligent Systems Software in Boca Raton, FL, announced Jan. 17 that the FDA had cleared its computer-aided detection (CAD) system, MammoReader. The product is designed to help

Intelligent Systems Software in Boca Raton, FL, announced Jan. 17 that the FDA had cleared its computer-aided detection (CAD) system, MammoReader. The product is designed to help in early detection of breast cancer by increasing the detection of subtle signs of cancer. The system is cleared for both screening and diagnostic use. Supporting the company's FDA application were clinical data from 327 cancer cases, which showed that breast cancer in 23% of the women diagnosed with the disease could have been discovered an average of 14 months earlier on screening mammograms, if MammoReader had been used, according to the company. MammoReader analyses are based on digitized mammograms. The systems, which will be marketed by Instrumentarium, will be priced at $99,500 and up.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.